MannKind (MNKD) delivered strong financial results for the fourth quarter — noteworthy for the best-ever quarterly sales of the inhaled insulin Afrezza and the product’s first-ever gross profit.

This is news largely because the words “MannKind” and “strong financial results” have never appeared together in a sentence. In almost all respects, MannKind has been a raging, insulin-delivery dumpster fire, so give management credit for a quarter that hints at a turnaround. There’s still a long way to go.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy